Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Australian Stock Exchange  >  CSL Limited    CSL   AU000000CSL8

CSL LIMITED

(CSL)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

CSL : update on ATAGI advice for AZ COVID-19 Vaccine

04/08/2021 | 08:24am EDT
CSL Statement in relation to updated ATAGI advice on AstraZeneca COVID-19 Vaccine
08 Apr 2021
news

CSL remains committed to meeting its contracted arrangements with the Australian Government and AstraZeneca for locally produced AstraZeneca COVID-19 vaccines. We will continue our focused and important efforts to manufacture this vaccine which remains critical for the protection of our most vulnerable populations.

We are proud of our unique role in Australia as the only onshore manufacturer that can produce this vaccine and remain dedicated to our ongoing contribution towards this effort.

- ends -

About CSL

CSL (ASX:CSL; USOTC:CSLLY) is a leading global biotechnology company with a dynamic portfolio of life-saving medicines, including those that treat haemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL - including our two businesses, CSL Behring and Seqirus - provides life-saving products to more than 70 countries and employs more than 27,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit Vita at CSLBehring.com/Vita and follow us on Twitter.com/CSL

For more information about CSL Limited, visit www.csl.com

Related News

  • share

Disclaimer

CSL Limited published this content on 08 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 April 2021 12:23:03 UTC.


© Publicnow 2021
All news about CSL LIMITED
04/13CALIFORNIA CONTRACTORS : New CSLB Procedure Requires Non-California Corporations..
AQ
04/12Australia shares slip after government scraps vaccination targets
RE
04/11Australian shares fall after abandoning of vaccination targets
RE
04/09Australia shares end lower as vaccine rollout hits snag
RE
04/08Australia shares snap 5-day rally as vaccine rollout suffers setback
RE
04/08Australia doubles Pfizer vaccine order as Astra clotting worries upend rollou..
RE
04/08ASTRAZENECA  : Australia backs Pfizer virus vaccine over AstraZeneca for under-5..
RE
04/08CSL  : update on ATAGI advice for AZ COVID-19 Vaccine
PU
04/07ASTRAZENECA  : Australia backs Pfizer virus vaccine over AstraZeneca for under-5..
RE
04/06ASTRAZENECA  : EU denies blocking 3.1 million AstraZeneca shots to Australia
RE
More news
Financials (USD)
Sales 2021 10 047 M - -
Net income 2021 2 293 M - -
Net Debt 2021 4 179 M - -
P/E ratio 2021 41,3x
Yield 2021 0,98%
Capitalization 94 625 M 94 537 M -
EV / Sales 2021 9,83x
EV / Sales 2022 9,37x
Nbr of Employees 27 000
Free-Float 99,8%
Chart CSL LIMITED
Duration : Period :
CSL Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CSL LIMITED
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 234,48 $
Last Close Price 207,91 $
Spread / Highest target 24,9%
Spread / Average Target 12,8%
Spread / Lowest Target -7,63%
EPS Revisions
Managers and Directors
NameTitle
Paul Roger Perreault Chief Executive Officer, Executive Director & MD
Joy Carolyn Linton Chief Financial Officer
Brian Anthony McNamee Chairman
Andrew Cuthbertson Chief Scientific Officer & Executive Director
William Mezzanotte Chief Medical Officer, EVP & Head-R&D
Sector and Competitors
1st jan.Capitalization (M$)
CSL LIMITED-5.26%94 537
WUXI BIOLOGICS (CAYMAN) INC.1.95%56 805
SAMSUNG BIOLOGICS CO.,LTD.-2.42%47 790
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.22.24%44 359
BIOGEN INC.8.55%40 716
ALEXION PHARMACEUTICALS, INC.0.83%34 613